title: Nanoparticle albumin-bound-Paclitaxel in the treatment of metastatic urethral adenocarcinoma: the significance of molecular profiling and targeted therapy.
abstract: Primary urethral cancer is rare and accounts for only 0.003% of all malignancies arising from the female genitourinary tract. Due to the rarity of this disease, no consensus exists regarding the optimal therapeutic approach. Nanoparticle albumin-bound-paclitaxel has been shown to be effective in the treatment of a number of malignancies including metastatic breast, pancreatic, and bladder cancer. We present a 67-year-old woman with advanced metastatic urethral adenocarcinoma resistant to two lines of chemotherapy (ifosfamide/paclitaxel/cisplatin and irinotecan/5-fluorouracil/leucovorin) that showed a dramatic response to nanoparticle albumin-bound-paclitaxel. This is the first case report to document the use and efficacy of nanoparticle albumin-bound-paclitaxel in the treatment of unresectable metastatic urethral cancer.
authors.affiliation: Department of Internal Medicine, Florida Hospital, Orlando, FL 32804, USA.
authors.forename: Yasmin M
authors.initials: YM
authors.lastname: Abaza
authors.affiliation: Cancer Institute of Florida, Florida Hospital, 2501 North Orange Avenue, Suite 689, Orlando, FL 32804, USA.
authors.forename: Carlos
authors.initials: C
authors.lastname: Alemany